Evidenced-Based Approach to Oropharynx Cancer, 2017
2017 AAO-HNSF Annual Meeting & OTO Experience
The incidence of HPV-associated oropharynx squamous cell carcinoma (OPSCC) continues to rise dramatically. Treatment strategies for these patients continue to evolve at rapidly because of new technologies such as proton therapy, novel systemic therapies and transoral robotic surgery (TORS). Current treatment approaches vary widely among institutions and national consensus guidelines remain vague. This course will review the current best evidence to guide management decisions relevant to general otolaryngologists and head and neck specialists alike with a focus on the role of TORS.
Description
The incidence of HPV-associated oropharynx squamous cell carcinoma (OPSCC) continues to rise dramatically. Treatment strategies for these patients continue to evolve at rapidly because of new technologies such as proton therapy, novel systemic therapies and transoral robotic surgery (TORS). Current treatment approaches vary widely among institutions and national consensus guidelines remain vague. This course will review the current best evidence to guide management decisions relevant to general otolaryngologists and head and neck specialists alike with a focus on the role of TORS.Learning Objectives: 1. Analyze recent advances in the treatment of oropharynx squamous cell carcinoma (OPSCC).2. Describe the current evidence supporting treatment strategies for OPSCC.3. Practice the rational application of transoral robotic surgery (TORS) to OPSCC.Faculty: Neil D. Gorss, MD (Intuitive Surgical: Unpaid consultant MedRobotics: Unpaid consultant), Chris Holsinger, MD (Nothing to disclose).
